@entity2629 is an ominous prognostic sign in @entity82 with @entity843 . To investigate whether other @entity8 are also prognostically significant, we studied the @entity916 - @entity1369 system and @entity1372 excretion (UNaV) in 75 @entity1 who had nonazotemic @entity82 with @entity843 and related these to survival. On the basis of plasma @entity916 activity @entity1 were classified in two groups. Group I included 34 @entity1 with normal @entity916 activity (1.13 +/- 0.69 ng/mL . h) and Group II, 41 @entity1 with high @entity916 activity (7.46 +/- 3.86 ng/mL . h). The two groups differed significantly (p less than 0.001) in plasma @entity1369 , UNaV, and wedged hepatic venous pressure but not in clinical features, liver function, glomerular filtration, and renal plasma flow. @entity1 of Group I lived significantly longer than those of Group II (the 50% survival rates were 28 months and 6 months, respectively). Survival curves obtained after grouping the @entity1 according to UNaV (higher and lower than 10 meq/d) were almost identical to those obtained according to @entity916 activity. The study results indicate that plasma @entity916 activity and UNaV are of prognostic value in nonazotemic @entity82 with @entity843 .

Plasma @entity916 activity and urinary XXXX excretion as prognostic indicators in nonazotemic @entity82 with @entity843 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal disturbances'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity1369 :: ('MESH:D000450', 'Chemical') :: ['aldosterone'] @entity843 :: ('MESH:D001201', 'Disease') :: ['ascites'] @entity1372 :: ('MESH:D012964', 'Chemical') :: ['sodium'] @entity2629 :: ('MESH:D053099', 'Disease') :: ['Azotemia'] @entity916 :: ('5972', 'Gene') :: ['renin']
@entity1372 :: (MESH:D012964,Chemical) :: ['sodium']
